Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.

× No keyword cloud information.

11 in total

Review 1. Evaluation of technologies approved for supplemental payments in the United States.

Authors: Timothy J Judson; Sanket S Dhruva; Rita F Redberg
Journal: BMJ Date: 2019-06-17

2. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Authors: Huseyin Naci; Olivier J Wouters; Radhika Gupta; John P A Ioannidis
Journal: Milbank Q Date: 2017-06 Impact factor: 4.911

3. The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.

Authors: Thomas J Hwang; Jonathan J Darrow; Aaron S Kesselheim
Journal: JAMA Date: 2017-12-05 Impact factor: 56.272

4. Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion.

Authors: Vanessa Boudewyns; Amie C O'Donoghue; Ryan S Paquin; Kathryn J Aikin; Kate Ferriola-Bruckenstein; Victoria M Scott
Journal: Oncologist Date: 2021-09-28

5. Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.

Authors: Sanket S Dhruva; Jonathan J Darrow; Aaron S Kesselheim; Rita F Redberg
Journal: J Gen Intern Med Date: 2022-02-09 Impact factor: 5.128

Review 6. Checkpoint Inhibitors, Palliative Care, or Hospice.

Authors: Mellar P Davis; Rajiv Panikkar
Journal: Curr Oncol Rep Date: 2018-01-19 Impact factor: 5.075

7. Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers.

Authors: H Kim Lyerly; Jun Ren; Renzo Canetta; Gi Hyun Kim; Sumimasa Nagai; Tomohiro Yamaguchi; Ken Hatogai; Hiroshi Katayama; Silvy Da Rocha Dias; Daniel McManus; Kathy Soltys; Zhimin Yang; Olufumilayo Olopade; Nancy Goodman; Greg Reaman; Thomas Gross
Journal: J Glob Oncol Date: 2018-12

8. Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update.

Authors: Ryan S Paquin; Vanessa Boudewyns; Amie C O'Donoghue; Kathryn J Aikin
Journal: Oncologist Date: 2022-02-03

Review 9. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors: Ping-Pin Zheng; Jin Li; Johan M Kros
Journal: Med Res Rev Date: 2017-09-01 Impact factor: 12.944

10. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.

Authors: Sana R Mostaghim; Joshua J Gagne; Aaron S Kesselheim
Journal: BMJ Date: 2017-09-07